We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
+15.56%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$118M
AUM Growth
+$20.3M
Cap. Flow
+$12.5M
Cap. Flow %
10.64%
Top 10 Hldgs %
96.23%
Holding
19
New
6
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
ECOR icon
electroCore
ECOR
+$7.2M
2
ENTX icon
Entera Bio
ENTX
+$2.99M
3
GLMD icon
Galmed Pharmaceuticals
GLMD
+$1.69M
4
CRBP icon
Corbus Pharmaceuticals
CRBP
+$344K
5
NAGE
Niagen Bioscience
NAGE
+$182K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABEO icon
1
Abeona Therapeutics
ABEO
$345M
$37.8M 32.09%
94,391
– –
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$29.6M 25.18%
749,815
– –
CRBP icon
3
Corbus Pharmaceuticals
CRBP
$170M
$19.8M 16.8%
130,462
+1,896
+1% +$344K
ECOR icon
4
electroCore
ECOR
$51.4M
$6.55M 5.57%
+26,481
New +$7.2M
AMPE
5
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$5.71M 4.85%
8,652
– –
KRYS icon
6
Krystal Biotech
KRYS
$9.88B
$4.46M 3.79%
300,000
– –
ENTX icon
7
Entera Bio
ENTX
$101M
$3M 2.55%
+475,540
New +$2.99M
GLMD icon
8
Galmed Pharmaceuticals
GLMD
$3.94M
$2.5M 2.12%
+1,167
New +$1.69M
NTBL
9
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
$1.97M 1.68%
25,622
– –
AVXL icon
10
Anavex Life Sciences
AVXL
$222M
$1.9M 1.61%
724,205
– –
ALDX icon
11
Aldeyra Therapeutics
ALDX
$91.7M
$987K 0.84%
124,096
– –
EIGR
12
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$918K 0.78%
2,508
– –
SNGX icon
13
Soligenix
SNGX
$5.5M
$813K 0.69%
3,494
– –
VNRX icon
14
VolitionRx Ltd
VNRX
$12M
$703K 0.6%
17,577
– –
EVOK
15
DELISTED
Evoke Pharma
EVOK
$688K 0.58%
1,910
– –
NAGE
16
Niagen Bioscience
NAGE
$256M
$178K 0.15%
+47,866
New +$182K
LPCN icon
17
Lipocine
LPCN
$17.1M
$65K 0.06%
+2,941
New +$70.1K
OTRK
18
DELISTED
Ontrak
OTRK
$61K 0.05%
+101
New +$53.5K
ADXSW
19
DELISTED
Advaxis Inc Warrants
ADXSW
$20K 0.02%
112,500
– –

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, Knoll Capital Management held 19 positions worth $118M, up 21% from $97.4M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Knoll Capital Management deployed $12.5M of net new capital in Q2 2018, opening 6 new positions and adding to 1 existing holding. Its largest new stake was electroCore: 26,481 shares worth $6.55M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Knoll Capital Management's largest Q2 2018 buy was electroCore: 26,481 shares worth $6.55M.
  • Knoll Capital Management added most to Corbus Pharmaceuticals in Q2 2018, an estimated $344K increase.
  • Knoll Capital Management's ten largest holdings make up 96% of its $118M portfolio in Q2 2018.
  • Knoll Capital Management opened 6 new positions and closed 0 in Q2 2018.
  • Knoll Capital Management's portfolio value rose 21% quarter-over-quarter to $118M.

Based on Knoll Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.